首页|表皮生长因子受体在胰腺腺鳞癌中的表达及临床意义

表皮生长因子受体在胰腺腺鳞癌中的表达及临床意义

Clinical study on the expression of EGFR in pancreatic adenosquamous carcinoma

扫码查看
目的 探讨表皮生长因子受体(EGFR)在胰腺腺鳞癌(PASC)中的表达及临床意义.方法 收集2016年1月至2021年12月于首都医科大学附属北京朝阳医院接受手术治疗的60例胰腺癌组织标本和8例正常胰腺组织标本.回顾性分析这60例患者的临床病理资料,包括男性23例,女性37例,年龄(62.7±10.2)岁,其中病理结果为PASC的20例,通过倾向性匹配同期胰腺导管腺癌(PDAC)40例.免疫组织化学染色(IHC)检测EGFR表达的积分光密度(IOD)值,荧光定量聚合酶链反应检测EGFR mRNA的表达差异,根据EGFR的IOD值中位数将20例PASC样本分为高、低表达两组,Kaplan-Meier生存分析比较EGFR表达对PASC患者预后的影响.结果 PASC组的癌组织IOD值为29.2(25.7,35.1),高于PDAC组的IOD值9.5(5.5,13.0),且均高于正常组织的2.4(1.7,3.1),差异均有统计学意义(均P<0.001).PASC组EGFR mRNA表达水平高于PDAC组[3.0(1.8,3.5)比1.2(0.8,1.2)],差异有统计学意义(P=0.0079).EGFR高表达组相较于低表达组生存时间更短(P=0.002).PASC组血管侵犯率高于PDAC组[40.0%(8/20)比17.5%(7/40)],差异有统计学意义(P=0.002).PASC组的中位生存时间为16.00(9.25,25.25)个月,低于PDAC组的21.50(11.25,40.75)个月,差异有统计学意义(P=0.033).PASC组术后累积生存率低于PDAC组,差异有统计学意义(P<0.028).结论 PASC组织中EGFR表达显著升高,且PASC患者预后不良.
Objective Exploration of epidermal growth factor receptor(EGFR)expression and its clinical significance in pancreatic adenosquamous carcinoma(PASC).Methods A total of 60 pancreatic cancer tissue samples and 8 normal pancreatic tissue samples were obtained from patients who were surgically treated at Beijing Chao-Yang Hospital,Capital Medical University from January 2016 to December 2021.A retrospective analysis of the clinical and pathological data of these 60 patients was conducted,including 23 males and 37 females with an age of(62.7±10.2)years.Among them,20 cases were pathologically diag-nosed as PASC,and 40 contemporaneous cases of pancreatic ductal adenocarcinoma(PDAC)were selected through propensity score matching.Immunohistochemistry(IHC)staining was used to measure the integrat-ed optical density(IOD)of EGFR expression,and quantitative polymerase chain reaction(qPCR)was employed to detect the expression differences of EGFR mRNA.Based on the median IOD value of EGFR,the 20 PASC samples were divided into two groups,high and low expression groups.Kaplan-Meier survival analysis was performed to compare the impact of EGFR expression on the prognosis of PASC patients.Results The IOD value of EGFR in PASC group(29.2[25.7,35.1])was significantly higher than that in the PDAC group[9.5(5.5,13.0)]and they both exceeded the value in normal tissues[2.4(1.7,3.1)],with statistical significances(all P<0.001).The level of EGFR mRNA expression in the PASC group was higher than that in the PDAC group[3.0(1.8,3.5)vs 1.2(0.8,1.2)],showing statistically significant difference(P=0.0079).Patients with high EGFR expression had shorter overall survival com-pared with patients with low expression(P=0.002).The incidence of vascular invasion in the PASC group[40.0%(8/20)]was higher than that in the PDAC group[17.5%(7/40)],with a significant difference(P=0.002).The median survival time for the PASC group was 16.00(9.25,25.25)months,which was shorter than that of the PDAC group 21.50(11.25,40.75)months,showing a statistically significant difference(P=0.033).The overall survival rate of the PASC group was lower than PDAC group(P=0.028).Conclusion EGFR expression is significantly elevated in PASC tissues and PASC patients have poor prognosis.

Pancreatic neoplasmsPancreatic adeno-squamous carcinomaEpidermal growth factor receptorTargeted therapy

付永纯、赵昕、吕少诚、胡志朝、贺强

展开 >

北京怀柔医院肝胆外科,北京 101400

首都医科大学附属北京朝阳医院肝胆外科,北京 100020

胰腺肿瘤 胰腺腺鳞癌 表皮生长因子受体 靶向治疗

2024

中华肝胆外科杂志
中华医学会

中华肝胆外科杂志

CSTPCD北大核心
影响因子:1.846
ISSN:1007-8118
年,卷(期):2024.30(1)
  • 21